Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 3
1949 3
1950 7
1951 5
1952 5
1953 3
1954 7
1955 5
1956 5
1957 10
1958 4
1959 7
1960 3
1961 4
1962 5
1963 16
1964 49
1965 35
1966 22
1967 45
1968 52
1969 42
1970 51
1971 66
1972 75
1973 65
1974 54
1975 170
1976 141
1977 123
1978 119
1979 114
1980 129
1981 149
1982 156
1983 195
1984 234
1985 224
1986 272
1987 279
1988 338
1989 363
1990 407
1991 404
1992 413
1993 395
1994 410
1995 448
1996 451
1997 449
1998 458
1999 475
2000 535
2001 608
2002 650
2003 725
2004 680
2005 758
2006 704
2007 794
2008 650
2009 694
2010 732
2011 782
2012 786
2013 819
2014 885
2015 1073
2016 1122
2017 1154
2018 1137
2019 1158
2020 1061
2021 1083
2022 934
2023 921
2024 380

Text availability

Article attribute

Article type

Publication date

Search Results

26,570 results

Results by year

Filters applied: . Clear all
Page 1
Glufosfamide: beta-D-Glc-IPM, D 19575.
[No authors listed] [No authors listed] Drugs R D. 2005;6(1):49-52. doi: 10.2165/00126839-200506010-00006. Drugs R D. 2005. PMID: 15801867 Review.
Glufosfamide [D 19575, beta-D-Glc-IPM] is a next-generation glucose conjugate of ifosfamide that is under development with Threshold Pharmaceuticals for the treatment of cancer. It is an alkylating agent in which isophosphoramide mustard, the alkylating …
Glufosfamide [D 19575, beta-D-Glc-IPM] is a next-generation glucose conjugate of ifosfamide that is under development with Thr …
The etiology of osteosarcoma.
Ottaviani G, Jaffe N. Ottaviani G, et al. Cancer Treat Res. 2009;152:15-32. doi: 10.1007/978-1-4419-0284-9_2. Cancer Treat Res. 2009. PMID: 20213384 Review.
Rapidly proliferating cells may be particularly susceptible to oncogenic agents and mitotic errors which lead to neoplastic transformation. ...Osteosarcoma has also been associated with the use of intravenous radium and Thorotrast. Exposure to alkylating agents …
Rapidly proliferating cells may be particularly susceptible to oncogenic agents and mitotic errors which lead to neoplastic transform …
Ambamustine. PTT119.
[No authors listed] [No authors listed] Drugs R D. 2003;4(2):119-21. doi: 10.2165/00126839-200304020-00007. Drugs R D. 2003. PMID: 12718568 No abstract available.
DNA Alkylation Damage by Nitrosamines and Relevant DNA Repair Pathways.
Fahrer J, Christmann M. Fahrer J, et al. Int J Mol Sci. 2023 Feb 28;24(5):4684. doi: 10.3390/ijms24054684. Int J Mol Sci. 2023. PMID: 36902118 Free PMC article. Review.
More recently, nitrosamines have been detected as impurities in various drugs. This is of particular concern as nitrosamines are alkylating agents that are genotoxic and carcinogenic. We first summarize the current knowledge on the different sources and chemical nat …
More recently, nitrosamines have been detected as impurities in various drugs. This is of particular concern as nitrosamines are alkylati …
Rethinking Alkylating(-Like) Agents for Solid Tumor Management.
Lajous H, Lelièvre B, Vauléon E, Lecomte P, Garcion E. Lajous H, et al. Trends Pharmacol Sci. 2019 May;40(5):342-357. doi: 10.1016/j.tips.2019.03.003. Epub 2019 Apr 9. Trends Pharmacol Sci. 2019. PMID: 30979523 Free article. Review.
Although old molecules, alkylating agents and platinum derivatives are still widely used in the treatment of various solid tumors. ...Thus, rethinking of the use of these pivotal antineoplastic agents appears critical to improve clinical outcomes in the manag …
Although old molecules, alkylating agents and platinum derivatives are still widely used in the treatment of various solid tum …
Temozolomide in malignant gliomas.
Yung WK. Yung WK. Semin Oncol. 2000 Jun;27(3 Suppl 6):27-34. Semin Oncol. 2000. PMID: 10866347 Review.
Glioblastoma multiforme and anaplastic astrocytoma are the most common primary central nervous system malignancies and are the major cause of morbidity/ mortality despite combined modality approaches. Temozolomide (TMZ), a novel, oral, second-generation alkylating agent, h …
Glioblastoma multiforme and anaplastic astrocytoma are the most common primary central nervous system malignancies and are the major cause o …
The mechanisms of cyclophosphamide-induced testicular toxicity and the protective agents.
Ghobadi E, Moloudizargari M, Asghari MH, Abdollahi M. Ghobadi E, et al. Expert Opin Drug Metab Toxicol. 2017 May;13(5):525-536. doi: 10.1080/17425255.2017.1277205. Epub 2016 Dec 29. Expert Opin Drug Metab Toxicol. 2017. PMID: 28019118 Review.
Cyclophosphamide (CP) is an alkylating antineoplastic agent with known toxicity to the male reproductive system. ...
Cyclophosphamide (CP) is an alkylating antineoplastic agent with known toxicity to the male reproductive system. ...
Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L, Opydo-Chanek M, Stojak M. Mazur L, et al. Anticancer Drugs. 2011 Jul;22(6):488-93. doi: 10.1097/CAD.0b013e328345e1e0. Anticancer Drugs. 2011. PMID: 21427562 Review.
Glufosfamide (beta-D-glucose-isophosphoramide mustard, D-19575) belongs to the oxazaphosphorine class. Glufosfamide is a novel glucose conjugate of ifosfamide in which isophosphoramide mustard, the alkylating metabolite of ifosfamide, is glycosidically linked …
Glufosfamide (beta-D-glucose-isophosphoramide mustard, D-19575) belongs to the oxazaphosphorine class. Glufosfamide is a novel …
Future directions for temozolomide therapy.
Yung WK. Yung WK. Semin Oncol. 2001 Aug;28(4 Suppl 13):43-6. doi: 10.1016/s0093-7754(01)90070-3. Semin Oncol. 2001. PMID: 11550138 Review.
Also under investigation are modifications to the temozolomide dosing schedule, other routes of administration, and treatment regimens that include temozolomide in combination with other chemotherapeutic and biologic agents. Temozolomide has the potential to be a useful ag …
Also under investigation are modifications to the temozolomide dosing schedule, other routes of administration, and treatment regimens that …
26,570 results
You have reached the last available page of results. Please see the User Guide for more information.